Skip to main content
Skip to navigation
Print subscriptions
Sign in
Search jobs
Search
US edition
US edition
UK edition
Australia edition
Europe edition
International edition
The Guardian - Back to home
The Guardian
News
Opinion
Sport
Culture
Lifestyle
Show
More
Show More
News
View all News
US news
US elections 2024
RNC Convention
World news
Environment
Ukraine
Soccer
Business
Tech
Science
Newsletters
Wellness
Opinion
View all Opinion
The Guardian view
Columnists
Letters
Opinion videos
Cartoons
Sport
View all Sport
Olympics 2024
Soccer
NFL
Tennis
MLB
MLS
NBA
NHL
F1
Golf
Culture
View all Culture
Film
Books
Music
Art & design
TV & radio
Stage
Classical
Games
Lifestyle
View all Lifestyle
Wellness
Fashion
Food
Recipes
Love & sex
Home & garden
Health & fitness
Family
Travel
Money
Support us
Print subscriptions
US edition
UK edition
Australia edition
Europe edition
International edition
Search jobs
Digital Archive
Guardian Licensing
About Us
The Guardian app
Video
Podcasts
Pictures
Inside the Guardian
Guardian Weekly
Crosswords
Wordiply
Corrections
Search jobs
Digital Archive
Guardian Licensing
About Us
AstraZeneca
May 2024
Nils Pratley on finance
Will AstraZeneca be the UK’s first £200bn company?
Nils Pratley
AstraZeneca aims to nearly double revenues to $80bn by 2030
AstraZeneca’s Covid vaccine is no more – but its remarkable success must not be forgotten
AstraZeneca withdraws Covid-19 vaccine worldwide, citing surplus of newer vaccines
April 2024
Nils Pratley on finance
The danger in saying yes to Pascal Soriot’s pay rise at AstraZeneca
Nils Pratley
AstraZeneca CEO’s £18.7m pay approved despite shareholder rebellion
March 2024
AstraZeneca claims Australian rules stopped it defending its vaccine during pandemic
AstraZeneca to buy Canadian cancer specialist Fusion for $2.4bn
When £17m isn’t enough: FTSE firms plead to pay bosses millions more
GlaxoSmithKline boss’s pay package jumps 50% to £12.7m
February 2024
AstraZeneca boss’s £17m pay package under fire
Weight-loss drugs need to become cheaper, says AstraZeneca boss
December 2023
Other lives
Felix Munkonge obituary
Other lives
: Specialist in cell biology who helped with the development of a Covid-19 vaccine and treatments for cystic fibrosis
AstraZeneca buys Chinese cancer therapy firm Gracell for $1.2bn
Gracell Biotechnologies acquisition marks China’s growing importance to the Anglo-Swedish drugmaker
AstraZeneca buys US vaccine company in $1.1bn deal
Britain’s biggest drugmaker acquires Seattle-based firm Icosavax, expanding vaccine and immune therapy business
November 2023
AstraZeneca makes big push into weight-loss market with obesity pill deal
UK drugmaker signs agreement with China’s Eccogene to work on an obesity and type 2 diabetes pill
August 2023
FTSE 100 bosses ‘given average pay rise of £500,000 in 2022’
CEOs received average increase of 16% while pay of many working for them failed to keep up with inflation
July 2023
Observer business profile
Pascal Soriot of AstraZeneca: ‘The climate crisis is a health crisis’
The man who led the drive to create a not-for-profit Covid vaccine is now focusing on the deaths caused by global heating and pollution
‘It’s naive to think this is in the best interests of the NHS.’ How Big Pharma’s millions are influencing healthcare
Observer investigation shows drug company money flows through the NHS, raising questions about conflict of interest
AstraZeneca stock value falls by nearly £14bn after cancer drug trial results
Shares close down 8% on concerns that new lung cancer drug may not be as successful as hoped
About 1,062 results for AstraZeneca
1
2
3
4
...
Explore more on these topics
Pharmaceuticals industry
Health
Medical research
Executive pay and bonuses
FTSE